Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression

[1]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[2]  S. Inoue,et al.  Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer , 2016, Oncotarget.

[3]  F. Shen,et al.  Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. , 2016, European journal of pharmacology.

[4]  G. Netto,et al.  Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis , 2016, Molecular carcinogenesis.

[5]  E. Plimack,et al.  Targeting Signaling Transduction Pathways in Bladder Cancer , 2015, Current Oncology Reports.

[6]  G. Carrieri,et al.  Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study , 2015, Therapeutic advances in urology.

[7]  L. Marchionni,et al.  Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma , 2015, PloS one.

[8]  S. Narumiya,et al.  Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. , 2015, Cancer research.

[9]  E. Suzuki,et al.  Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer , 2015, BMC Cancer.

[10]  E. Suzuki,et al.  Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer , 2015, BMC Cancer.

[11]  A. Fernández-Martínez,et al.  Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells , 2015, Cellular and Molecular Life Sciences.

[12]  D. Hess,et al.  COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation , 2015, Molecular Cancer Research.

[13]  Philip Levy Ho,et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.

[14]  G. Andriole,et al.  Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study , 2014, Clinical Cancer Research.

[15]  G. Kristiansen,et al.  Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. , 2014, American journal of cancer research.

[16]  Yi Li,et al.  GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. , 2014, American journal of cancer research.

[17]  T. Uchiumi,et al.  EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer , 2013, Prostate Cancer and Prostatic Disease.

[18]  G. Piazza,et al.  NSAIDs Inhibit Tumorigenesis, but How? , 2013, Clinical Cancer Research.

[19]  T. Uchiumi,et al.  Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. , 2013, Endocrine-related cancer.

[20]  Verena Jendrossek,et al.  Targeting apoptosis pathways by Celecoxib in cancer. , 2013, Cancer letters.

[21]  E. Messing,et al.  Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder , 2012, BJU international.

[22]  Jorge Yao,et al.  Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. , 2011, Endocrine-related cancer.

[23]  R. Morishita,et al.  PGE2‐EP2 signalling in endothelium is activated by haemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF‐κB , 2011, British journal of pharmacology.

[24]  T. Uchiumi,et al.  Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells , 2011, BJU international.

[25]  Adolfo Cruz,et al.  Effects of Capecitabine and Celecoxib in Experimental Pancreatic Cancer , 2010, Pancreatology.

[26]  Sheau-Fang Yang,et al.  Nuclear factor‐κB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma , 2010, BJU international.

[27]  J. W. Lee,et al.  Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. , 2010, Urology.

[28]  B. Craig,et al.  Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder , 2010, Molecular Cancer Therapeutics.

[29]  Y. Daaka,et al.  Prostaglandin E2 Promotes Lung Cancer Cell Migration via EP4-βArrestin1-c-Src Signalsome , 2010, Molecular Cancer Research.

[30]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[31]  G. Kuchel,et al.  Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. , 2009, Prostaglandins & other lipid mediators.

[32]  Jun Liu,et al.  Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells , 2009, Digestive Diseases and Sciences.

[33]  D. Dhawan,et al.  Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells , 2008, Molecular Cancer Therapeutics.

[34]  M. O’Banion,et al.  Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism. , 2007, Cancer research.

[35]  K. Lundholm,et al.  EP1–4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease‐specific mortality , 2007, International journal of cancer.

[36]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[37]  L. Dwyer-Nield,et al.  Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. , 2006, Anticancer research.

[38]  K. Ohba,et al.  Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract , 2006, Virchows Archiv.

[39]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[40]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[41]  O. Cussenot,et al.  Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. , 2005, European urology.

[42]  K. Nakanishi,et al.  Expression of Hypoxia-Inducible Factor-1α Protein Predicts Survival in Patients with Transitional Cell Carcinoma of the Upper Urinary Tract , 2005, Clinical Cancer Research.

[43]  H. Kanetake,et al.  Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. , 2005, The Journal of urology.

[44]  V. Rangnekar,et al.  Suppression of PTEN Expression by NF-κB Prevents Apoptosis , 2004, Molecular and Cellular Biology.

[45]  J. J. Sung,et al.  Chemoprevention of gastric cancer by celecoxib in rats , 2004, Gut.

[46]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.

[48]  Pan‐Chyr Yang,et al.  Cyclooxygenase-2 Inducing Mcl-1-dependent Survival Mechanism in Human Lung Adenocarcinoma CL1.0 Cells , 2001, The Journal of Biological Chemistry.

[49]  R. Anderson,et al.  Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors , 2001, British Journal of Cancer.

[50]  Michael A Davies,et al.  MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells , 2000, Oncogene.

[51]  Y. Boie,et al.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.

[52]  D. Bostwick,et al.  Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. , 1999, Cancer research.

[53]  M. Knowles,et al.  Somatic mutation of PTEN in bladder carcinoma , 1999, British Journal of Cancer.

[54]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[55]  T. Kuczek,et al.  Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. , 1994, Journal of veterinary internal medicine.

[56]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[57]  C. Reznikoff,et al.  Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene. , 1988, Carcinogenesis.

[58]  T. Tamada,et al.  Plasma prostaglandin levels in patients with gynecologic malignancies and its fluctuations during chemotherapeutically-induced gastrointestinal toxicity. , 1987, Japanese journal of clinical oncology.

[59]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.